SCHEMBL24252713

SCHEMBL24252713

COc1ccc(B2OC(C)(C)C(C)(C)O2)cc1-c1ccc2c(N)cnnc2c1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.41
PDE10A Q9Y233 12/20 0.39
CSF1R P07333 1/20 0.37
SNCA P37840 1/20 0.36
PDGFRB P09619 1/20 0.34
KDR P35968 1/20 0.34
LRRK2 Q5S007 1/20 0.34
LPL P06858 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30467616 1.00 DHFR (0.41) DHFRPDE10ACSF1RSNCAPDGFRB
Trifluoroacetic Acid SCHEMBL30467704 0.91 F2 (0.40) DHFRPDE10ACSF1RPDGFRBKDR
SCHEMBL30467652 0.89 DHFR (0.38) DHFRPDE10ALRRK2
SCHEMBL24252749 0.89 DHFR (0.38) DHFRPDE10ALRRK2
SCHEMBL24252418 0.89 PDE10A (0.35) DHFRPDE10ACSF1RSNCAPDGFRB
SCHEMBL24252349 0.88 DHFR (0.39) DHFRPDE10ALRRK2
SCHEMBL30467744 0.88 DHFR (0.39) DHFRPDE10ALRRK2
SCHEMBL24252750 0.88 DHFR (0.39) DHFRPDE10ALRRK2
SCHEMBL30467659 0.88 DHFR (0.39) DHFRPDE10ALRRK2
SCHEMBL25209984 0.86 DHFR (0.33) DHFRPDE10APDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DHFR 1380/4885PDE10A 1950/4885CSF1R 963/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DHFR 1380/4885PDE10A 1950/4885CSF1R 963/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 DHFR 1380/4885PDE10A 1950/4885CSF1R 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.